Lorinda Burgess
About Lorinda Burgess
Lorinda A. Burgess is an independent director of AngioDynamics, Inc. (ANGO), age 63, serving since July 2023. She was CFO and VP of Finance for the Americas at Medtronic (2015–2023), with prior leadership roles in customer care and cardiovascular finance; she holds a BA in Communication and Political Science from the University of Michigan and an MBA from Ohio State University . She is independent under Nasdaq standards and currently serves on ANGO’s Audit and Compensation Committees .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Medtronic, Inc. | CFO & VP Finance, Americas | 2015–2023 | Senior financial leadership across a Fortune 200 medtech portfolio |
| Medtronic, Inc. | VP Customer Care, Americas & Western Europe | — | Commercial/customer operations leadership |
| Medtronic, Inc. | VP Finance, Cardiovascular Group Sales & Marketing | — | Finance oversight for CV commercial functions |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Stepan Company (NYSE: SCL) | Director | — | Board service; network relevance to ANGO given another ANGO director also serves on Stepan |
Board Governance
- Committee assignments: Member, Audit Committee; Member, Compensation Committee; not on Nominating/Compliance/Governance. Audit Committee chaired by Wesley E. Johnson; Compensation Committee chaired by Eileen O. Auen .
- Independence: The Board determined Burgess and six other directors are independent under Nasdaq standards .
- Attendance and engagement: FY2025 Board met 4 times; each incumbent director attended >75% of Board and committee meetings. Audit Committee met 8 times with full attendance; Compensation Committee met 4 times with full attendance .
- Executive sessions and oversight: Independent directors meet privately; strong risk oversight via Audit (financial/internal controls), Compensation (risk in incentives), and Nominating/Compliance committees .
Fixed Compensation
| Component | FY2025 Terms | Source |
|---|---|---|
| Annual cash retainer (non‑employee directors) | $65,000 | |
| Chair add’l retainer – Board | $55,000 | |
| Chair add’l retainer – Audit | $25,000 | |
| Chair add’l retainer – Compensation | $17,500 | |
| Chair add’l retainer – Nominating/Compliance/Governance | $17,500 | |
| Member add’l retainer – Audit | $10,000 | |
| Member add’l retainer – Compensation | $7,500 | |
| Member add’l retainer – Nominating/Compliance/Governance | $7,500 |
| Director | Period | Fees Earned/Paid in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|---|
| Lorinda Burgess | FY2025 | 79,022 | 152,003 | 231,025 |
| Lorinda Burgess | FY2024 | 44,721 | 152,006 | 196,727 |
- Stock ownership guidelines: Directors must hold shares equal to 3x base cash retainer within 36 months; all directors are currently in compliance .
Performance Compensation
- Equity structure: Annual director equity grant comprised wholly of RSUs; standard vesting one year from grant date; grant-date fair value ≈ $152,000 .
- FY2025 change: On July 16, 2025, the Board approved granting restricted shares to non-employee directors with immediate vesting (i.e., accelerated vesting for that year’s grant) .
| Metric | FY2024 | FY2025 |
|---|---|---|
| Director equity vehicle | RSUs, 1-year vest | Restricted shares, immediate vest |
| Grant-date fair value (approx.) | $152,000 | $152,000 |
Note: Director compensation is not tied to operating performance metrics (no director-specific EBITDA/EPS/TSR gates); RSUs/restricted shares are time/structure-based .
Other Directorships & Interlocks
| External Board | Role | Interlock at ANGO | Details |
|---|---|---|---|
| Stepan Company (NYSE: SCL) | Director | Yes | ANGO director Jan Stern Reed also serves on Stepan’s board . |
- Compensation committee interlocks: ANGO discloses none for FY2025 (and as of proxy date) .
Expertise & Qualifications
- Financial leadership: Former CFO & VP Finance, Medtronic Americas; brings financial, strategic, and medtech operational expertise .
- Audit committee suitability: Board deems Audit members independent and financially literate; committee oversees financial reporting, internal controls, compliance, auditor independence .
- Sector experience: Deep medtech commercial and operational background relevant to ANGO’s growth transformation .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Shares Acquirable within 60 Days |
|---|---|---|---|
| Lorinda A. Burgess | 55,257 | <1% | — |
- Shares outstanding at 9/18/2025: 41,076,119; no director or executive officer owned >1% .
- Hedging/pledging: Company policy prohibits hedging and pledging of Company securities by directors and employees; margin accounts also prohibited .
Insider Trades (Form 4)
| Date Filed | Event Date | Type | Detail |
|---|---|---|---|
| 2025-07-18 | 2025-07-16 | Form 4 | Director stock award grant; filed on EDGAR and ANGO investor site |
| 2024-07-17 | 2024-07-17 | Stock Award (Grant) | Director equity grant noted by Yahoo Insider Transactions |
| 2023-07-21 | 2023-07-19 | Form 4 | 17,041 RSUs granted as regular annual director compensation; RSUs terms disclosed |
Governance Assessment
- Board effectiveness: Burgess contributes CFO-level financial expertise and medtech operating insight; active roles on Audit and Compensation align with her background .
- Independence and attendance: Independent under Nasdaq; strong engagement evidenced by full committee attendance and >75% overall attendance in FY2025 .
- Alignment: Director equity ownership guidelines (3x retainer) with current compliance, and prohibition on hedging/pledging support shareholder alignment .
- Compensation structure signals: FY2025 immediate vesting of restricted shares for directors reduces retention/long-term alignment compared to one-year RSU vesting—monitor as a potential softening of governance rigor year-over-year .
- Interlocks: Dual ANGO–Stepan board overlap (Burgess and Jan Stern Reed) can facilitate information flow but warrants routine conflict monitoring if vendor/customer relationships emerge; ANGO reports no related-party transactions in FY2025 .
- Shareholder sentiment: Strong 2024 Say‑on‑Pay support at ~91.9%, indicating positive investor confidence in compensation governance (primarily for NEOs, but reflective of overall governance culture) .
- RED FLAGS: None disclosed specific to Burgess—no related‑party transactions; no committee interlocks; no hedging/pledging; note immediate vesting of director equity in FY2025 as a governance point to watch .